• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Ablation tech developer Adagio Medical to go public in SPAC deal

February 15, 2024 By Sean Whooley

adagio-largeArya Sciences Acquisition Corp IV agreed to a business combination with Adagio Medical, taking the cardiac ablation company public.

Upon the closing of the transaction, Adagio is set to become a subsidiary of Aja Holdco, still operating under its existing management team and under the name “Adagio Medical.” Arya expects to list the combined company’s common stock on the Nasdaq market under the “ADGM” ticker.

Arya, a special purpose acquisition corporation (SPAC), is the latest to try and take a medtech company public through this type of merger. SPAC mergers took the medtech industry by storm a few years ago but produced varying results in the years following. Read here about some of the outcomes of these planned acquisitions.

In this SPAC deal, investors committed to participate in the transaction in the form of $20 million in convertible debt. They also committed $22 million in equity financing. Investors include affiliates of Perceptive Advisors, RA Capital Management, RTW Investments and ATW Partners.

Adagio Medical develops cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias. Those include paroxysmal and persistent AFib, atrial flutter, and ventricular tachycardia.

“The business combination agreement and Adagio Medical’s evolution to a public company is a natural next step in our relationship with Perceptive Advisors and other investor groups who have long supported Adagio Medical’s innovations aimed to improve the efficacy of cardiac ablations,” said Olav Bergheim, president and CEO of Adagio Medical.  “We are expanding the clinical trials program for Adagio Medical’s proprietary ultra-low temperature cryo (ULTC) and pulsed field cryoablation (PFCA) technologies, with some of the pivotal data and new product launches expected in the first half of 2024.”

Bergheim believes the SPAC merger ensures sufficient capital to support European commercialization for its ULTC system. The company also believes it can initiate a U.S. pivotal IDE trial and advance its ULTC and PFCA clinical programs for treating AFib.

More about the SPAC merger taking Adagio Medical public

According to a news release, the transaction implies a post-transaction fully diluted equity value of $128 million. The companies expect current Adagio shareholders to convert 100% of their existing equity interests into shares of the combined company.

They expect current Adagio investors to own approximately 10.2% of the combined company. Perceptive and Arya expect to hold approximately 58.2%. The respective boards of both companies approved the proposed transaction. They expect to complete the merger in the second quarter of 2024, subject to shareholder approval.

“When Arya IV was formed, our objective was to identify a company with the potential to successfully address a significant, unmet need and to advance the treatment of patients,” said Adam Stone, chief investment officer of Perceptive Advisors and CEO of ARYA. “In Adagio Medical, we’ve come to believe that the company’s innovative cardiac ablation technology, thoughtful commercialization strategy, and experienced leadership team make it an exceptional fit to meet our objectives.”

Filed Under: Catheters Tagged With: Adagio Medical

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS